UnitedHealth Group (NYSE: UNH) delivered its most convincing earnings beat in years on Tuesday April 21, reporting Q1 2026 adjusted EPS of $7.23 against a consensus estimate of $6.65, a $0.58 beat that sent the stock surging approximately 8 percent during the session to around $342 — a meaningful recovery for a company that had been one of the most heavily punished large-cap names on the market, down roughly 45 percent over the prior twelve months heading into the print.
Revenue of $111.7 billion came in ahead of the $109.8 billion estimate, up 2 percent year on year from $109.6 billion in Q1 2025. Operating earnings reached $9.0 billion, with cash flows from operations of $8.9 billion representing 1.4 times net income. Adjusted EBITDA of $10.37 billion beat the $9.51 billion estimate by 9 percent. The company raised its full-year 2026 adjusted EPS outlook to greater than $18.25 per share from the prior guidance of greater than $17.75, and maintained its full-year revenue guidance of more than $439 billion.
The single most important data point in the release was not the earnings beat but the medical care ratio, which came in at 83.9 percent for Q1 2026 versus 84.8 percent in Q1 2025. That year-on-year improvement represents concrete evidence that the medical cost repricing actions management executed through 2025 are functioning as intended. UnitedHealth CEO Stephen Hemsley, who took over the role following Andrew Witty’s departure, characterised Q1 as a demonstration that the company is “continuing to help simplify and modernise health care.”
Medicare Advantage trends were confirmed by UnitedHealthcare CEO Tim Noel as tracking the pricing assumptions management had built into its 2026 plan, with “modest favorability in government programs” cited.
The company is also in the process of exiting 2.3 to 2.8 million members from unprofitable contracts as part of a disciplined margin recovery strategy.
Morgan Stanley holds UNH as a Top Pick with a $375 price target. Jefferies has a $373 target. Of the 29 analysts covering the stock, the Street mean target sits at $360.46. The stock’s recovery from the depths of its DOJ investigation, cyberattack remediation charges and Medicare Advantage implosion remains incomplete — the shares were still down roughly 15 percent year-to-date heading into Tuesday — but the Q1 print provides the first clear evidence since late 2024 that the Business is stabilising in a durable way.